{"title":"错过了一个技巧？安非他酮在英国用于抑郁症的药物治疗","authors":"Michael Browning, Philip J. Cowen","doi":"10.1192/bjp.2025.50","DOIUrl":null,"url":null,"abstract":"<p>Bupropion is not licensed as an antidepressant in the UK, limiting its use. We highlight bupropion’s distinct pharmacological profile and its potential benefits in treatment-resistant depression and people experiencing selective serotonin reuptake inhibitor-induced sexual dysfunction. The National Health Service repurposing medicines programme could improve equity of access for UK patients.</p>","PeriodicalId":22495,"journal":{"name":"The British Journal of Psychiatry","volume":"33 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Missing a trick? Bupropion for the pharmacological treatment of depression in the UK\",\"authors\":\"Michael Browning, Philip J. Cowen\",\"doi\":\"10.1192/bjp.2025.50\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Bupropion is not licensed as an antidepressant in the UK, limiting its use. We highlight bupropion’s distinct pharmacological profile and its potential benefits in treatment-resistant depression and people experiencing selective serotonin reuptake inhibitor-induced sexual dysfunction. The National Health Service repurposing medicines programme could improve equity of access for UK patients.</p>\",\"PeriodicalId\":22495,\"journal\":{\"name\":\"The British Journal of Psychiatry\",\"volume\":\"33 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-04-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The British Journal of Psychiatry\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1192/bjp.2025.50\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The British Journal of Psychiatry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1192/bjp.2025.50","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Missing a trick? Bupropion for the pharmacological treatment of depression in the UK
Bupropion is not licensed as an antidepressant in the UK, limiting its use. We highlight bupropion’s distinct pharmacological profile and its potential benefits in treatment-resistant depression and people experiencing selective serotonin reuptake inhibitor-induced sexual dysfunction. The National Health Service repurposing medicines programme could improve equity of access for UK patients.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
